These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

418 related articles for article (PubMed ID: 34512623)

  • 21. Predictive biomarkers for response to immune checkpoint inhibitors in lung cancer: PD-L1 and beyond.
    Uruga H; Mino-Kenudson M
    Virchows Arch; 2021 Jan; 478(1):31-44. PubMed ID: 33486574
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BRAF mutations and BRAF mutation functional class have no negative impact on the clinical outcome of advanced NSCLC and associate with susceptibility to immunotherapy.
    Wiesweg M; Preuß C; Roeper J; Metzenmacher M; Eberhardt W; Stropiep U; Wedeken K; Reis H; Herold T; Darwiche K; Aigner C; Stuschke M; Schildhaus HU; Schmid KW; Falk M; Heukamp L; Tiemann M; Griesinger F; Schuler M
    Eur J Cancer; 2021 May; 149():211-221. PubMed ID: 33872981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunotherapy in advanced non-small-cell lung cancer with
    Liu F; Yuan X; Jiang J; Chu Q
    Immunotherapy; 2020 Nov; 12(16):1195-1207. PubMed ID: 32985295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. AXL expression reflects tumor-immune cell dynamics impacting outcome in non-small cell lung cancer patients treated with immune checkpoint inhibitor monotherapy.
    Rayford A; Gärtner F; Ramnefjell MP; Lorens JB; Micklem DR; Aanerud M; Engelsen AST
    Front Immunol; 2024; 15():1444007. PubMed ID: 39238637
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational variant allele frequency profile as a biomarker of response to immune checkpoint blockade in non-small cell lung Cancer.
    Gao R; Lou N; Li L; Xie T; Xing P; Tang L; Yao J; Han X; Shi Y
    J Transl Med; 2024 Jun; 22(1):576. PubMed ID: 38890738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decision model for durable clinical benefit from front- or late-line immunotherapy alone or with chemotherapy in non-small cell lung cancer.
    Zhao J; Wang L; Zhou A; Wen S; Fang W; Zhang L; Duan J; Bai H; Zhong J; Wan R; Sun B; Zhuang W; Lin Y; He D; Cui L; Wang Z; Wang J
    Med; 2024 Aug; 5(8):981-997.e4. PubMed ID: 38781965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report.
    Naito T; Umemura S; Nakamura H; Zenke Y; Udagawa H; Kirita K; Matsumoto S; Yoh K; Niho S; Motoi N; Aokage K; Tsuboi M; Ishii G; Goto K
    Thorac Cancer; 2019 May; 10(5):1285-1288. PubMed ID: 30972962
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Lu J; Zhong R; Lou Y; Hu M; Yang Z; Wang Y; Chen Y; Zou B; Zhang W; Wang H; Han B
    Front Immunol; 2021; 12():732125. PubMed ID: 34603310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Impact of NOTCH Pathway Alteration on Tumor Microenvironment and Clinical Survival of Immune Checkpoint Inhibitors in NSCLC.
    Li X; Wang Y; Li X; Feng G; Hu S; Bai Y
    Front Immunol; 2021; 12():638763. PubMed ID: 34305884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
    Sun D; Qian H; Wang J; Xie T; Teng F; Li J; Xing P
    Cell Commun Signal; 2022 Oct; 20(1):156. PubMed ID: 36229854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutational landscape of SWI/SNF complex genes reveal correlation to predictive biomarkers for immunotherapy sensitivity in lung adenocarcinoma patients.
    Xu H; Chen HC; Yang L; Yang G; Liang L; Yang Y; Tang H; Bao H; Wu X; Shao Y; An G; Wang Y
    ESMO Open; 2023 Jun; 8(3):101585. PubMed ID: 37327699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of nomogram based on immune-related gene FGFR4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors.
    Wang L; Ren Z; Yu B; Tang J
    J Transl Med; 2021 Jan; 19(1):22. PubMed ID: 33407583
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence of SWI/SNF genomic alterations in cancer and association with the response to immune checkpoint inhibitors: A systematic review and meta-analysis.
    Wang N; Qin Y; Du F; Wang X; Song C
    Gene; 2022 Aug; 834():146638. PubMed ID: 35680019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with
    Oya Y; Kuroda H; Nakada T; Takahashi Y; Sakakura N; Hida T
    Int J Mol Sci; 2020 Apr; 21(7):. PubMed ID: 32283823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of Efficacy and Prognosis Analysis of Stage III-IV SMARCA4-deficient 
Non-small Cell Lung Cancer Treated by PD-1 Immune Checkpoint Inhibitors plus 
Chemotherapy and Chemotherapy].
    Wang X; Tu M; Jia H; Liu H; Wang Y; Wang Y; Jiang N; Lu C; Zhang G
    Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):659-668. PubMed ID: 37985152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cutting-edge progress of immune-checkpoint blockade in lung cancer.
    Zhou F; Qiao M; Zhou C
    Cell Mol Immunol; 2021 Feb; 18(2):279-293. PubMed ID: 33177696
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC).
    Jeanson A; Tomasini P; Souquet-Bressand M; Brandone N; Boucekine M; Grangeon M; Chaleat S; Khobta N; Milia J; Mhanna L; Greillier L; Biemar J; Nanni I; Ouafik L; Garcia S; Mazières J; Barlesi F; Mascaux C
    J Thorac Oncol; 2019 Jun; 14(6):1095-1101. PubMed ID: 30738221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC.
    Ishii H; Azuma K; Kawahara A; Kinoshita T; Matsuo N; Naito Y; Tokito T; Yamada K; Akiba J; Hoshino T
    Thorac Cancer; 2020 Apr; 11(4):950-955. PubMed ID: 32061060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Granzyme B is correlated with clinical outcome after PD-1 blockade in patients with stage IV non-small-cell lung cancer.
    Hurkmans DP; Basak EA; Schepers N; Oomen-De Hoop E; Van der Leest CH; El Bouazzaoui S; Bins S; Koolen SLW; Sleijfer S; Van der Veldt AAM; Debets R; Van Schaik RHN; Aerts JGJV; Mathijssen RHJ
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461348
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.